Candel Therapeutics (CADL) closed an offering of 12 million shares at $6 apiece and prefunded warrants to raise $92 million in gross proceed.
The warrants are for purchasing up to 3.33 million shares at $5.99 per prefunded warrant to purchase one share of common stock, the company said late Monday in a statement.
The sale includes 2 million shares sold following the full exercise of the underwriters' option.
Candel intends to use the net proceeds to continue the development of its product candidates, including preparing the submission of a biologics license application for CAN-2409 in prostate cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。